Autoplaque vs DeepTek CXR Analyzer
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary need is a precise, quantitative assessment of coronary artery disease using CT angiography. This tool is ideal for cardiologists and radiologists focused on detailed plaque characterization and luminal stenosis measurements to inform heart attack risk prediction and guide treatment strategies. Its workstation-based deployment allows for in-depth analysis and clinician review.
View Autoplaque →Choose DeepTek CXR Analyzer if…
Choose DeepTek CXR Analyzer if you require an AI-powered solution for efficient, high-volume screening and detection of diverse pathologies on chest X-rays. This tool is best suited for radiology departments aiming to reduce radiologist workload and improve diagnostic throughput by automatically highlighting suspicious regions across lung, pleural, and cardiac findings. Its cloud or on-premise deployment and PACS integration support streamlined workflow automation.
View DeepTek CXR Analyzer →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | DeepTek CXR Analyzer |
|---|---|---|
| Pricing | Unknown | Global access pricing available for eligible public sector and not-for-profit healthcare providers in 138 low- and middle-income countries, offering unlimited ai analyses per connected x-ray unit, installation, user training, product updates, maintenance, and technical support via an annual subscription. |
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | On-premise and Cloud offerings. The solution supports online, offline, and hybrid deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
DeepTek CXR AnalyzerDeepTek CXR Analyzer emphasizes seamless DICOM-based PACS integration and intelligent segregation of scans, which suggests a highly integrated and efficient workflow for radiologists. Autoplaque, being workstation-based, might require a separate application launch, potentially adding steps to the clinical workflow.
Clinical Value
TieBoth tools are FDA-cleared and offer significant clinical value in their respective domains. Autoplaque provides quantitative analysis for critical cardiac risk prediction, while DeepTek CXR Analyzer offers broad detection across multiple pathologies on a high-volume imaging modality, improving efficiency and diagnostic accuracy.
Pricing & Value
DeepTek CXR AnalyzerDeepTek CXR Analyzer offers a transparent 'pay-per-use' pricing model, which provides clarity and flexibility for budgeting and scalable adoption. Autoplaque's pricing is not disclosed, making it difficult to assess its value proposition without further information.
Enterprise Readiness
DeepTek CXR AnalyzerDeepTek CXR Analyzer explicitly states HIPAA compliance, BAA availability, and offers flexible cloud and on-premise deployment options, which are crucial for enterprise integration. Autoplaque's workstation-based deployment and lack of explicit compliance statements make its enterprise readiness less clear.
Innovation
TieBoth tools demonstrate significant innovation. Autoplaque provides advanced AI-powered quantitative analysis for coronary plaque and stenosis, aiding in heart attack risk prediction. DeepTek CXR Analyzer innovates by offering broad detection of 28 findings on chest X-rays and intelligent scan segregation to significantly improve workflow efficiency.
Support & Docs
TieNeither the provided structured facts nor readily available public information explicitly detail the support channels or documentation for either Autoplaque or DeepTek CXR Analyzer. Therefore, it is not possible to distinguish between them on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | DeepTek CXR Analyzer |
|---|---|---|
| Primary Imaging Modality & Focus | CT angiography images for quantitative analysis of coronary plaques and luminal stenoses. | Chest X-ray analysis for detection of suspicious regions across lung, pleural, and cardiac pathologies. |
| Company | Cedars-Sinai Medical Center: AIM | DeepTek Medical Imaging Pvt |
| Target Specialties | Cardiology, Radiology | Cardiology, Pulmonology, Radiology |
| Key Analysis Capabilities | AI-powered quantitative analysis of atherosclerotic plaque, detection and characterization of coronary artery plaque, measurement of luminal stenoses, automated vessel, plaque, and lumen segmentation. | AI-Powered Computer-Assisted Detection (CADe) for Chest X-rays, detection of 28 findings covering lung, pleural, cardiac pathologies, and hardware, automatic identification, categorization, and highlighting of suspicious regions of interest (ROIs). |
| Stated Workflow Impact/Benefit | Aiding in heart attack risk prediction and treatment guidance. | Reduces radiologist workload by 30-50% and boosts productivity by 2x-3x; intelligent segregation of scans into 'AI Finding-Negative' and 'AI Finding-Positive'. |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and DeepTek CXR Analyzer.